Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Assets (2018 - 2025)

Historic Current Assets for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $249.2 million.

  • Arcturus Therapeutics Holdings' Current Assets fell 2467.23% to $249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.2 million, marking a year-over-year decrease of 2467.23%. This contributed to the annual value of $306.0 million for FY2024, which is 2085.18% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Current Assets is $249.2 million, which was down 2467.23% from $274.5 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Current Assets ranged from a high of $470.0 million in Q1 2021 and a low of $246.7 million during Q3 2022
  • In the last 5 years, Arcturus Therapeutics Holdings' Current Assets had a median value of $375.8 million in 2024 and averaged $354.1 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Current Assets skyrocketed by 63714.46% in 2021 and then tumbled by 4140.14% in 2022.
  • Arcturus Therapeutics Holdings' Current Assets (Quarter) stood at $379.0 million in 2021, then rose by 6.43% to $403.3 million in 2022, then fell by 4.15% to $386.6 million in 2023, then fell by 20.85% to $306.0 million in 2024, then fell by 18.56% to $249.2 million in 2025.
  • Its last three reported values are $249.2 million in Q3 2025, $274.5 million for Q2 2025, and $278.8 million during Q1 2025.